Reflux Drugs OK With Blood Thinners

Taking antacids with anti-clotting drugs doesn't change outcomes after a heart attack, researchers find

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Abdominoplasty • Acidophilus • Adhesions • Alzheimer's Disease More... Related Healthscout Videos Saving Memories with a Shake: The Alzheimer's Drink Copycat Conditions: Stroke Mimics eFeed: Teaching Toddlers How to Eat Don't Wait on Your Prostate More... Related Animations • Alzheimer's Disease Video Animation • Angioplasty • Coronary Bypass Surgery • Erectile Dysfunction More... Related Drug Information • Accupril • Aciphex • Actonel • Altace More... Related News Articles • Smoking May Up Cancer Risk in Barrett's Esophagus Patients • More Than 4 Million Americans Have New Knee • More People Need Training in Lifesaving Epinephrine Use, Advocates Say • Health Tip: Healthier Ways to Prepare Potatoes More...

TUESDAY, Sept. 1 (HealthDay News) -- Antacids don't interfere with anti-clotting drugs such as Plavix and Effient in patients who have suffered a heart attack or unstable angina, a new study finds.

The results counter other studies that concluded that a class of antacids known as proton pump inhibitors (PPIs) could block the effect of anti-clotting drugs. Doctors often prescribe PPIs along with anti-clotting drugs to reduce the risk of gastrointestinal bleeding.

Text Continues Below

---

"The current findings provide some reassurance to clinicians that PPIs and clopidogrel [Plavix] can be safely combined in patients in whom there is a strong indication to use both drugs," said lead researcher Dr. Michelle O'Donoghue, an investigator in the TIMI Study Group at Brigham and Women's Hospital in Boston.

As to why the findings differ from earlier results, O'Donoghue said the answer may lie in the patients themselves and in the type of data analyzed.

"Patients who are treated with a PPI may differ quite markedly from other patients," she said. "In particular, there is concern that PPIs are often administered to sicker patients and that this may help to explain why patients on a PPI seem to do more poorly than other patients."

In the current study, the researchers adjusted for these differences, O'Donoghue said.

"Another advantage of the current study is that it was done within the confines of a clinical trial," she said. "In a clinical trial, all endpoints are strictly defined and adjudicated so there may be less of a risk for bias."

The report is published in the Sept. 1 online edition of The Lancet, to coincide with the presentation of the results Monday at the European Society of Cardiology Congress in Barcelona.

For the study, O'Donoghue's group looked at the effects of PPIs like Prilosec in two trials, the TRITON-TIMI 38 trial and a smaller trial. In the TRITON-TIMI 38 trial, researchers randomly assigned 13,608 patients to clopidogrel (Plavix) or prasugrel (Effient) after having a heart attack or unstable angina.

Page:  1 | 2 | Next >>